Plasma cell leukemia: Clinical manifestations and management

Abstract

Author(s): Yuvraj Parmar, Madhumati Varma, Vaibhav Kaushik, Rajnish Kumar, Ravindra S. Patil, Devanshu J. Patel

The prevalent and aggressive plasma cell dyscrasia is Plasma Cell Leukaemia (PCL). The average patient survival for those with PCL is assessed in months, and their prognosis is negative. PCL can manifest on its own or after a plasma cell myeloma prodrome. Clinically aggressive PCL patients frequently demonstrate severe disease stages, bone marrow failure, extramedullary disease, a presence about certain immune phenotypic markers, such as Cluster of Differentiation 20 (CD20) expression and CD56 absence. Historically, palliative care has been the mainstay of PCL therapy, with only a smallest percentage of patients experiencing a long-lasting remission. Although uncertain if current drugs both allogeneic and autologous stem cell transplantation may be impacted by medications such as bortezomib and lenalidomide, recent research indicates that using these treatments helps PCL patients' poor prognoses

Share this article